Ads
related to: experimental prostate cancer drugs- Patient Resources
Download informative brochures for
patients and caregivers.
- Find An Imaging Site
Locate the nearest imaging site
or contact customer service.
- Talk To Your Doctor
Review questions to start a
conversation with your doctor.
- Reimbursement Support
The patient support program
can assist insurance assessment.
- Patient Resources
Search results
Results from the WOW.Com Content Network
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
Seviteronel (developmental codes VT-464 and, formerly, INO-464) is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. [1]
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
The candidate, JANX007, reduced prostate-specific (PSA) antigen levels in a majority of the 23 patients who received the drug, the company said late on Monday, adding that deeper reductions were ...
Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca. [1] It is an endothelin receptor antagonist. [2] Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA. It failed a phase III clinical trial for prostate cancer, [3] but other trials are ...
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Masofaniten, also known by its developmental code name EPI-7386, is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer.
For premium support please call: 800-290-4726 more ways to reach us
Ads
related to: experimental prostate cancer drugs